Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-PSMA-617
- Development stage
- Phase 2
- Lead developer
- Universitat Heidelberg
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
68Ga-PSMA-617 is a diagnostic radiopharmaceutical used in positron emission tomography/computed tomography (PET/CT) imaging to detect prostate-specific membrane antigen (PSMA)-expressing tumors, most notably in prostate cancer. It consists of the ligand PSMA-617 labeled with the radioisotope gallium-68, which emits positrons for PET imaging. The compound binds specifically to PSMA, a transmembrane protein highly expressed on prostate cancer cells and some other tumor types. After intravenous administration, 68Ga-PSMA-617 accumulates in PSMA-expressing tissues, allowing for sensitive and specific visualization of primary and metastatic lesions using PET/CT scans. This agent is primarily used for staging, restaging, and evaluating response to therapy in patients with prostate cancer[2][7][9].
- Other names
- gallium ga 68-psma-617[68ga]ga-psma-617
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 68Ga-PSMA-617.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-PSMA-617.